Matches in SemOpenAlex for { <https://semopenalex.org/work/W2981773686> ?p ?o ?g. }
Showing items 1 to 51 of
51
with 100 items per page.
- W2981773686 endingPage "S604" @default.
- W2981773686 startingPage "S604" @default.
- W2981773686 abstract "The SACT options for aNSCLC continue to increase each year with approvals of more effective therapies that improve long-term outcomes, as seen with immunotherapies (IO). Our aim was to examine real-world trends in SACT distribution and sequence from first- to second-line (1L-2L) for squamous aNSCLC from 2011-2018 at US community oncology practices. This study used the nationwide Flatiron Health de-identified, EHR-derived database (cutoff: 31Jan2019). Eligible patients were adults who initiated 1L SACT from Jan2011-Jun2018 for aNSCLC with squamous histology, excluding patients with known EGFR/ALK-positive tumors. Descriptive analyses included patients receiving ≥1 SACT dose, assigning all SACT regimens to mutually exclusive classes in hierarchical order (combination regimens assigned by highest component), from highest to lowest: (1) PD1/PD-L1 inhibitor (anti-PD1/L1)-based, (2) EGFR/ALK TKI-based, (3) platinum-based chemotherapy combination with vascular endothelial growth factor inhibitor (PBC+VEGF), (4) PBC only, (5) single agent chemotherapy, (6) others. The 2L regimens were examined for patients with 1L SACT initiation only through 2017 to enable sufficient follow-up. Results were stratified by years and by pre-IO and post-IO years of 1L initiation, defined as 2011-2014 and 2015-2018, respectively, based on the earliest IO approval for 2L therapy in Mar2015. For 1L therapy, in the pre-IO period, most patients were prescribed PBC (80%), and post-IO, most patients were prescribed PBC (68%) or anti-PD1/L1 (21%). Among patients prescribed 1L therapy, the percentages who received 2L therapy were 44%-53% following 1L PBC and 25%-37% following 1L anti-PD1/L1, with 19% of 2017 1L anti-PD1/L1 starts still on 1L therapy (table). PBC remain the most common 1L SACT prescribed through mid-2018 for patients with squamous aNSCLC at US community oncology practices. Prescribing of PD1/PD-L1 inhibitors as 1L has gradually increased since regulatory approval starting in 2015. Approximately one-half of patients with squamous aNSCLC prescribed 1L PBC are treated with 2L therapy." @default.
- W2981773686 created "2019-11-01" @default.
- W2981773686 creator A5008659083 @default.
- W2981773686 creator A5034912444 @default.
- W2981773686 creator A5039994328 @default.
- W2981773686 creator A5066861614 @default.
- W2981773686 creator A5086954528 @default.
- W2981773686 date "2019-10-01" @default.
- W2981773686 modified "2023-09-30" @default.
- W2981773686 title "P1.16-42 Real-World Trends in Systemic Anticancer Therapy (SACT) for Squamous Advanced NSCLC (aNSCLC) in the US, 2011–2018" @default.
- W2981773686 doi "https://doi.org/10.1016/j.jtho.2019.08.1268" @default.
- W2981773686 hasPublicationYear "2019" @default.
- W2981773686 type Work @default.
- W2981773686 sameAs 2981773686 @default.
- W2981773686 citedByCount "0" @default.
- W2981773686 crossrefType "journal-article" @default.
- W2981773686 hasAuthorship W2981773686A5008659083 @default.
- W2981773686 hasAuthorship W2981773686A5034912444 @default.
- W2981773686 hasAuthorship W2981773686A5039994328 @default.
- W2981773686 hasAuthorship W2981773686A5066861614 @default.
- W2981773686 hasAuthorship W2981773686A5086954528 @default.
- W2981773686 hasBestOaLocation W29817736861 @default.
- W2981773686 hasConcept C126322002 @default.
- W2981773686 hasConcept C143998085 @default.
- W2981773686 hasConcept C2776694085 @default.
- W2981773686 hasConcept C71924100 @default.
- W2981773686 hasConceptScore W2981773686C126322002 @default.
- W2981773686 hasConceptScore W2981773686C143998085 @default.
- W2981773686 hasConceptScore W2981773686C2776694085 @default.
- W2981773686 hasConceptScore W2981773686C71924100 @default.
- W2981773686 hasIssue "10" @default.
- W2981773686 hasLocation W29817736861 @default.
- W2981773686 hasOpenAccess W2981773686 @default.
- W2981773686 hasPrimaryLocation W29817736861 @default.
- W2981773686 hasRelatedWork W2023576770 @default.
- W2981773686 hasRelatedWork W2367105124 @default.
- W2981773686 hasRelatedWork W2369677035 @default.
- W2981773686 hasRelatedWork W2371666691 @default.
- W2981773686 hasRelatedWork W2373226427 @default.
- W2981773686 hasRelatedWork W2378355431 @default.
- W2981773686 hasRelatedWork W2791179561 @default.
- W2981773686 hasRelatedWork W2796582438 @default.
- W2981773686 hasRelatedWork W3018911986 @default.
- W2981773686 hasRelatedWork W2912578505 @default.
- W2981773686 hasVolume "14" @default.
- W2981773686 isParatext "false" @default.
- W2981773686 isRetracted "false" @default.
- W2981773686 magId "2981773686" @default.
- W2981773686 workType "article" @default.